RESUMEN

Aim: This study aims to establish the potential reliability and validity of miRNA-182 as a diagnostic tool in oncology, and hence to contribute to the decision-making process in clinical settings. Materials & methods: To further evaluate the role of miRNA-182 as a cancer biomarker, we conducted a search of the PubMed, Cochrane Library, Wanfang and China National Knowledge Infrastructure databases of existing literature. Conclusion: These results suggest that miRNA-182 could function as a potential molecular marker for cancer detection and diagnosis. The effect of miRNA-182 on tumor development should be further studied to confirm these results and add to the current understanding of its role in cancer.

A meta-analysis involves integrating the results from various studies to create a comprehensive understanding or view of the research topic. This review with meta-analysis presents an exhaustive evaluation of the effectiveness of a tiny molecule in our cells that helps control what our genes do named miRNA-182 as a signal that indicates a certain disease or condition for a variety of cancer types which we also called biomarkers. By assembling and analyzing a broad spectrum of research papers, the study assesses the specificity, sensitivity and overall diagnostic accuracy of miRNA-182 in cancer detection. The analysis incorporates diverse studies, ensuring an inclusive assessment of miRNA-182 across different types and stages of cancer. The review presents data from numerous clinical trials and studies, providing an in-depth examination of the variations in miRNA-182 levels between cancer patients and healthy individuals. Meta-analysis findings suggest that miRNA-182 demonstrates high diagnostic precision, surpassing traditional biomarkers in certain instances. This evidence underscores its potential value in clinical settings, notably in cancers where early detection is essential for effective treatment. Highlighting the emerging significance of miRNA biomarkers in the study of cancer, this review emphasizes the potential of miRNA-182 in enhancing early cancer detection, which could profoundly influence treatment outcomes. The findings propose that miRNA-182 may substantially improve early cancer detection and patient outcomes, indicating a substantial stride forward in tools and tests used to detect and understand cancer. Finally, the review advocates for larger, more diverse sample sizes and standardization of methodologies. These improvements will further validate miRNA-182's reliability as a cancer biomarker, establishing its diagnostic capabilities and promoting its integration into clinical practice.

Asunto(s)

RESUMEN

Both Qing-Ying decoction (QYD), a Traditional Chinese Medicine (TCM), and secukinumab, a fully humanized anti-interleukin-17A monoclonal antibody, have been used to treat patients with plaque psoriasis. The combined application of TCM and biologics in the treatment of psoriasis, however, has not been investigated. We enrolled a total of 68 patients with plaque psoriasis in our prospective study, and randomly assigned them to either the study group (treated with secukinumab plus QYD), or the control group (treated with secukinumab alone). After 12- and 16-week treatment, the Psoriasis Area and Severity Index (PASI) score and the TCM score were significantly reduced in both the study and the control groups. However, the reduction in PASI and TCM scores was more significant in the study group than in the control group (12-week: PASI: 5.29 ± 0.27 vs 8.87 ± 0.38, respectively; P < .01; TCM: 5.83 ± 0.21 vs 12.39 ± 1.23, respectively; P < .01; 16-week: PASI score: 4.76 ± 0.18 vs 8.36 ± 0.31, respectively; TCM score: 4.98 ± 0.19 vs 11.27 ± 1.13, respectively; P < .01). The total treatment efficacy rate was significantly higher in the study group (97.1%) than the control group (76.5%; P = .012). The number of CD3+ and CD4+ T cells was increased, while the number of CD8+ T cells was decreased after treatment in both groups, with more significant changes in the study group (P < .01). QYD may enhance the therapeutic outcome of secukinumab in the treatment of plaque psoriasis by further suppressing chronic skin inflammation, as well as reducing adverse events and patients' psychological stress.

Asunto(s)